Small molecule inhibitors of urokinase-type plasminogen activator

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 773-786

  Rockway, Tood W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Benzo b thiophene carboxamidine; Guanidine; Naphthamidine; Plasminogen activator inhibitor 1 (PAI 1); Urokinase; Urokinase receptor; Urokinase type plasminogen activator (uPA); WX UK1

Indexed keywords

AMIDINE; AMINO ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BENZYLAMINE DERIVATIVE; CARBOLINE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; CYCLOPEPTIDE; GROWTH FACTOR; GUANIDINE DERIVATIVE; HEPARIN; INDOLOAMIDINE DERIVATIVE; ISOTHIURONIUM DERIVATIVE; NAPHTHAMIDINE DERIVATIVE; PEPTOID; PHENYLPROPIONIC ACID DERIVATIVE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHODAMINE; SERINE PROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; WX UK 1; WX UK1;

AMINO TERMINAL SEQUENCE; BREAST CARCINOMA; CELL ADHESION; CELL INVASION; CELL MIGRATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME BINDING; EXTRACELLULAR MATRIX; HUMAN; KRINGLE DOMAIN; NONHUMAN; PATENT; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT;

EID: 0038647770     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.773     Document Type: Review

References (60)

1. NO AUTHORS LISTED: Cancer Facts and Figures. American Cancer Society Monograph (2002):1-45.
2. COUSSENS, LM, FINGLETON B, MATRISIAN LM: Matrix metalloprotease inhibitors and cancer: trials and tribulations. Science (2002) 295:2387-2392.
3. 2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem. (1990) 265(11 ):6453-6460.
4. SCHMITT M, JANICKE F, MONIWA N et al.: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance Biol. Chem. Hoppe Seyler (1992) 373(7):611-622.
5. DUFFY MJ: Plasminogen activators and cancer. Blood Coagul. Fibrinolysis (1990) 1(6):681-687.
6. BUSSO N, SO A: Urokinase in rheumatoid arthritis: causal or coincidental? Ann. Rheum. Dis. (1997) 56(12):705-706.
7. RONDAY HK, SMITS HH, QUAX PH et al.: Bone matrix degradation by the plasminigen activation system. Possible mechanism of bone destruction in arthritis. Br. J. Rheumatol. (1997) 36:9-15.
8. CARMELIET P, MOONS L, LIJNEN R et al.: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genetics (1997) 17(4):439-444.
9. NODA-HEINY H, DAUGHERTY A, SOBEL BE: Augmented urokinase receptor expression in atheroma. Arterioscler. Thromb. Vasc. Biol. (1995) 15(1):37-43.
10. HEYMANS S, LUTTUN A, NUYENS D: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. (1999) 5(10):1135-1142.
11. REUNING U, MAGDOLEN V, WILHELM O et al.: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int. J. Oncology (1998) 13(5):893-906.
12. EVANS DM, SLOAN-STAKLEFF K, ARVAN M, GUYTON DP: Time and dose dependency of the suppression of pulmonary metastasis of rat mammary cancer by amiloride. Clin. Exp. Metastasis (1998) 16:353-357.
13. BANERJI A, FERNANDES A, BANE S, AHIRE S: The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. Cancer Lett. (1998) 129:15-20.
14. RABBANI SA, HARAKIDAS P, DAVIDSON DJ, HENKIN J, MAZAR AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer (1995) 63(6):840-845.
15. ALONSO DF, TEJERA AM, FARIAS EF, BAL DE KIER JOFFE E, GOMEZ DE: Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anti-Cancer Res. (1998) 18:4499-4504.
16. SHAPIRO RL, DUQUETTE JG, ROSES DF et al.: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. (1996) 56(15):3597-3604.
17. IGNAR DM, ANDREWS JL, WITHERSPOON SM et al.: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp. Metastasis (1998) 16:9-20.
18. XING RH, RABBANI A: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer (1996) 67:423-429.
19. MUELLER BM, YU YB, LAUG WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in SCID/SCID mice. Proc. Natl. Acad. Sci. USA (1995) 92:205-209.
20. FOEKENS JA, BUESSECKER F, PETERS HA et al.: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. (1995) 55(7):1423-1427.
21. FLEISHER M: Prognostic markers other than hormone receptors in breast cancer. J. Clin. Ligand Assay (1998) 21:41-46.
22. GRONDAHL-HANSEN J, CHRISTENSEN IJ, BRIAND P et al.: Plasminogen activator inhibitor Type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin. Cancer Res. (1997) 3(2):233-239.
23. BAJOU K, NOEL A, GERARD RD et al.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. (1998) 4(8):923-928.
24. KIM SJ, SHIBA E, KOBAYASHI T et al.: Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin. Cancer Res. (1998) 4(1):177-182.
25. HARBECK N, DETTMAR P, THOMSSEN C et al.: Prognostic impact of tumor biological factors on survival in nodenegative breast cancer. Anti-Cancer Res. (1998) 18:2187-2198.
26. KWAAN HC, WANG J, SVOBODA K, DECLERCK PJ: Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer (2000) 82:1702-1706.
27. MAZAR A, HENKIN J, GOLDFARB RH: The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis (1999) 3:15-32.
28. GRONDAHL-HANSEN J, CHRISTENSEN IJ, ROSENQUIST C et al.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. (1993) 53(11):2513-2521.
29. MA D, GERARD RD, LI XY, ALIZADEH H, NIEDERKORN JY: Inhibition of metastasis of intraocular melanomas by adenoviral gene transfer of plasminogen activator inhibitor Type 1 (PAI-1) in an athymic mouse model. Blood (1997) 90:2738-2746.
30. SOFF GA, SANDEROWITZ J, GATELY S et al.: Expression of plasminogen activator inhibitor Type 1 in human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis and metastasis to lung and liver in athymic mouse model. J. Clin. Invest. (1995) 96(6):2593-2600.
31. 3 binding to vitronectin. Nat. Med. (1996) 383:441-443.
32. KJOLLER L, KANSE SM, KIRKEGAARD T et al.: Plasminogen activator inhibitor-1 represses integrin and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. (1997) 232:420-429.
33. MCMAHON GA, PETITCLERC E, STEFANSSON S et al.: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. (2001) 276(36):33964-33968.
34. PRAUS M, COLLEN D, GERARD RD: Both uPA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulates HT1080 fibrosarcoma cell metastasis. Int. J. Cancer (2002) 102:584-591.
35. STEPHENS RW, BOKMAN AM, MYOHANEN HT et al.: Heparin binding to the urokinase kringle domain. Biochemistry (1992) 31(33):7572-7579.
36. HANSEN AP, PETROS AM, MEADOWS RP et al.: Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 33(16):4847-4864.
37. 1H]-NMR characterization of the urokinase kringle module. Structural, but not functional, relatedness to homologous domains. J. Biol. Chem. (1993) 268(19):13858-13868.
38. LI X, BOKMAN AM, LLINAS M, SMITH RA, DOBSON CM: Solution structure of the kringle domain from urokinase-type plasminogen activator. J. Mol. Biol. (1994) 235(5):1548-1559.
39. KIM KS, HONG YK, JOE YA et al.: Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem. (2003) 278(13):11449-11456.
40. APPELLA E, ROBINSON EA, ULLRICH SJ et al.: The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. (1987) 262(10):4437-4440.
41. MAGDOLEN V, RETTENBERGER P, KOPPITZ M et al.: Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. (1996) 237(3):743-751.
42. SCHMIEDEBERG N, SCHMITT M, ROLZ C et al.: Synthesis, solution structure and biological evaluation of urokinase-type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem. (2002) 45(23):4984-4994.
43. SPRAGGON G, PHILLIPS C, NOWAK UK et al.: The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure (1995) 3(7):681-691.
44. NIENABER V, WANG J, DAVIDSON D, HENKIN J: Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J. Biol. Chem. (2000) 275(10):7239-7248.
45. NIENABER VL, DAVIDSON D, EDALJI R et al.: Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure (2000) 8(5):553-563.
46. NIENABER VL, RICHARDSON PL, KLIGHOFER V, BOUSKA JJ, GIRANDA VL, GREER J: Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. (2000) 18(10):1105-1108.
47. ZESLAWSKA E, SCHWEINITZ A, KARCHER A et al.: Crystals of the urokinase-type plasminogen activator variant β c-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J. Mol. Biol. (2000) 301:465-475.
48. GOODSON RJ, DOYLE MV, KAUFMAN SE, ROSENBERG S: High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Nat. Acad. Sci. USA (1994) 91(15):7129-7133.
49. PLOUG M, OSTERGAARD S, GARDSVOLL H et al.: Peptide derived antagonists of the urokinase receptor. Biochemistry (2001) 40(40):12157-12168.
50. MAGDOLEN V, BURGLE M, DE PRADA NA et al.: Cyclo19,31[D-Cys19]-uPA 19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. (2001) 382(8):1197-205.
51. KE SH, COOMBS GS, TACHIAS K, COREY DR, MADISON EL: Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. (1997) 272(33):20456-20462.
52. STURZEBECHER J, VIEWEG H, STEINMETZER T et al.: 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. (1999) 9(21):3147-3152.
53. SPENCER JR, MCGEE D, ALLEN D et al.: 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(15):2023-2026.
54. MACKMAN RL, HUI HC, BREITENBUCHER JG et al.: 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(15):2019-2022.
55. WILSON KJ, ILLIG CR, SUBASINGHE N et al.: Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors. Bioorg. Med. Chem. Lett. (2001) 11(7):915-918.
56. RUDOLPH MJ, ILLIG CR, SUBASINGHE NL et al.: Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(3):491-495.
57. TOWLE MJ, LEE A, MADUAKOR EC, SCHWARTZ CE, BRIDGES AJ, LITTLEFIELD BA: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. (1993) 53(11):2553-2559.
58. NO AUTHORS LISTED: Selective urokinase inhibitors based on substituted aryl guanidines. Exp. Opin. Ther. Patents (2001) 11(12):1975-1977.
59. BARBER CG, DICKINSON RP: Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl)guanidines. Bioorg. Med. Chem. Lett. (2002) 12(2):185-187.
60. BARBER CG, DICKINSON RP, HORNE VA: Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines. Bioorg. Med. Chem. Letters (2002) 12(2):181-184